Rachel K Redmann1, Deepak Kaushal2, Nadia Golden1, Breeanna Threeton1, Stephanie Z Killeen1, Philip J Kuehl3, Chad J Roy1,4. 1. Infectious Disease Aerobiology, Division of Microbiology, Tulane National Primate Research Center, Covington, Louisiana, USA. 2. Southwest National Primate Research Center, Texas Biomedical Research Institute, San Antonio, Texas, USA. 3. Lovelace Biomedical Research Institute, Albuquerque, New Mexico, USA. 4. Department of Microbiology and Immunology, Tulane School of Medicine, New Orleans, Louisiana, USA.
Abstract
Background: Bacillus Calmette-Guérin (BCG) is a vaccine used to protect against tuberculosis primarily in infants to stop early infection in areas of the world where the disease is endemic. Normally administered as a percutaneous injection, BCG is a live significantly attenuated bacteria that is now being investigated for its potential within an inhalable vaccine formulation. This study investigates the feasibility and performance of two jet and two vibrating mesh nebulizers aerosolizing BCG and the resulting particle characteristics and residual viability of the bacteria postaerosolization. Methods: A jet nebulizer (Collison), outfitted either with a 3- or 6-jet head, was compared with two clinical nebulizers, the vibrating mesh Omron MicroAir and Aerogen Solo devices. Particle characteristics, including aerodynamic particle sizing, was performed on all devices within a common aerosol chamber configuration and comparable BCG innocula concentrations. Integrated aerosol samples were collected for each generator and assayed for bacterial viability using conventional microbiological technique. Results: A batch lot of BCG (Danish) was grown to titer and used in all generator assessments. Aerosol particles within the respirable range were generated from all nebulizers at four different concentrations of BCG. The jet nebulizers produced a uniformly smaller particle size than the vibrating mesh devices, although particle concentrations by mass were similar across all devices tested with the exception of the Aerogen Solo, which resulted in a low concentration of BCG aerosols. Conclusions: The resulting measured viable BCG aerosol concentration fraction produced by each device approximated one another; however, a measurable decrease of efficiency and overall viability reduction in the jet nebulizer was observed in higher BCG inoculum starting concentrations, whereas the vibrating mesh nebulizer returned a remarkably stable viable aerosol fraction irrespective of inoculum concentration.
Background: Bacillus Calmette-Guérin (BCG) is a vaccine used to protect against tuberculosis primarily in infants to stop early infection in areas of the world where the disease is endemic. Normally administered as a percutaneous injection, BCG is a live significantly attenuated bacteria that is now being investigated for its potential within an inhalable vaccine formulation. This study investigates the feasibility and performance of two jet and two vibrating mesh nebulizers aerosolizing BCG and the resulting particle characteristics and residual viability of the bacteria postaerosolization. Methods: A jet nebulizer (Collison), outfitted either with a 3- or 6-jet head, was compared with two clinical nebulizers, the vibrating mesh Omron MicroAir and Aerogen Solo devices. Particle characteristics, including aerodynamic particle sizing, was performed on all devices within a common aerosol chamber configuration and comparable BCG innocula concentrations. Integrated aerosol samples were collected for each generator and assayed for bacterial viability using conventional microbiological technique. Results: A batch lot of BCG (Danish) was grown to titer and used in all generator assessments. Aerosol particles within the respirable range were generated from all nebulizers at four different concentrations of BCG. The jet nebulizers produced a uniformly smaller particle size than the vibrating mesh devices, although particle concentrations by mass were similar across all devices tested with the exception of the Aerogen Solo, which resulted in a low concentration of BCG aerosols. Conclusions: The resulting measured viable BCG aerosol concentration fraction produced by each device approximated one another; however, a measurable decrease of efficiency and overall viability reduction in the jet nebulizer was observed in higher BCG inoculum starting concentrations, whereas the vibrating mesh nebulizer returned a remarkably stable viable aerosol fraction irrespective of inoculum concentration.
Authors: A Roderick Escombe; Clarissa Oeser; Robert H Gilman; Marcos Navincopa; Eduardo Ticona; Carlos Martínez; Luz Caviedes; Patricia Sheen; Armando Gonzalez; Catherine Noakes; David A J Moore; Jon S Friedland; Carlton A Evans Journal: Clin Infect Dis Date: 2007-04-09 Impact factor: 9.079
Authors: Andrew D White; Charlotte Sarfas; Laura S Sibley; Jennie Gullick; Simon Clark; Emma Rayner; Fergus Gleeson; Martí Català; Isabel Nogueira; Pere-Joan Cardona; Cristina Vilaplana; Mike J Dennis; Ann Williams; Sally A Sharpe Journal: Pharmaceutics Date: 2020-04-25 Impact factor: 6.321
Authors: Alyssa C Fears; William B Klimstra; Paul Duprex; Amy Hartman; Scott C Weaver; Kenneth S Plante; Divya Mirchandani; Jessica Ann Plante; Patricia V Aguilar; Diana Fernández; Aysegul Nalca; Aysegul Totura; David Dyer; Brian Kearney; Matthew Lackemeyer; J Kyle Bohannon; Reed Johnson; Robert F Garry; Doug S Reed; Chad J Roy Journal: Emerg Infect Dis Date: 2020-06-22 Impact factor: 6.883
Authors: A Roy; M Eisenhut; R J Harris; L C Rodrigues; S Sridhar; S Habermann; L Snell; P Mangtani; I Adetifa; A Lalvani; I Abubakar Journal: BMJ Date: 2014-08-05